



Study schema



ICON6: Cediranib with platinum-based chemotherapy in 'platinum-sensitive' relapsed ovarian cancer




Progression-free survival - all three arms



	Chemo.	Conc.	Maint.
PFS events, n (%)	112 (94.9)	152 (87.4)	139 (84.8)
Median, months	8.7	10.1	11.1
Log-rank test (trend)		p=0.0003	
HR vs. Chemo only (95% CI)		0.67 (0.53–0.87)	0.57 (0.44–0.74)
Restricted means, months	9.4	11.4	12.5

Chemo.	118	90	24	8	3
Conc.	174	152	53	20	12
Maint.	164	148	65	21	7

Overall survival



Chemo.	118	106	89	46	27	11
Maint.	164	159	139	89	48	22